HCPLive Network

The Challenges of Treating Autoimmune Hepatitis

 
Autoimmune hepatitis often responds well to steroid therapy but identifying the disease and the best approach to management is filled with complexities, said Paul Martin, MD, professor of medicine, and division chief of Hepatology at Leonard M. Miller School of Medicine, University of Miami, who spoke this week at a joint conference of the American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy in Coronado, California.
 
Autoimmune hepatitis has characteristic clinical, serological, and histological features but many tests used in its medical management are not specific for the condition, noted Martin.
 
“We need to keep an open mind when we are evaluating patients with autoimmune hepatitis,” said Martin, speaking about the difficulties of diagnosing the condition.
 
The disease is steroid responsive, so a revised diagnosis may be in order if a patient does not respond to therapy within a few weeks.
 
A helpful tool is the fairly recent development of diagnostic criteria for autoimmune hepatitis, which assigns points based on the presence of a number of factors, including auto antibodies. It provides a useful checklist when evaluating a patient, said Martin.


Further Reading
The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
Among individuals without diabetes, a higher level of hemoglobin A1c is associated with advanced coronary artery calcification progression, according to research published online Oct. 16 in Diabetes Care.
More Reading
The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.